Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$12.06

2.09 (20.96%)

11:37
10/12/18
10/12
11:37
10/12/18
11:37

Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.

  • 19

    Oct

  • 12

    Oct

IOVA Iovance Biotherapeutics
$12.06

2.09 (20.96%)

09/06/18
RILY
09/06/18
NO CHANGE
Target $24
RILY
Buy
Moffitt data has little read-across to Iovance platform, says B. Riley FBR
Preliminary clinical data from a Moffitt-sponsored trial of tumor infiltrating lymphocyte therapy in lung cancer has little read-across to Iovance Biotherapeutics' TIL platform, B. Riley FBR analyst Madhu Kumar tells investors in a research note. He reiterates a Buy rating on Iovance with a $24 price target. The stock in morning trading is down 13%, or $2.25, to $14.70.
09/13/18
JEFF
09/13/18
NO CHANGE
Target $31
JEFF
Buy
Feedback on Moffitt TIL study appears positive, says Jefferies
Jefferies analyst Biren Amin hosted a call with an oncologist at Moffitt Cancer Center to review the initial data from this first non-small cell lung cancer tumor infiltrating lymphocytes study. The doctor highlighted the large unmet need in NSCLC patients who failed to respond to anti-PD-1 therapy and feels the 100% disease control rate achieved in the first eight refractory patients to nivo is promising, Amin tells investors in a research note. Further, the oncologist believes the limited duration of response could improve in a second NSCLC study incorporating key "biomarkers," the analyst points out. Amin believes Iovance Biotherapeutics could incorporate some of these key learnings into its two Phase I/II NSCLC studies. The analyst keeps a Buy rating on Iovance with a $31 price target.
09/25/18
COWN
09/25/18
NO CHANGE
COWN
Outperform
Iovance Biotherapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker said the recent weakness in Iovance is a buying opportunity. The analyst noted the company's results from the Moffitt-run study of TILS in NSCLC were deemed mild and somewhat disappointing. He believes the data has no read-through to the ongoing melanoma trial, making the weakness an attractive entry point. Peaker reiterated his Outperform rating on Iovance shares.
10/12/18
OPCO
10/12/18
NO CHANGE
Target $25
OPCO
Outperform
Iovance Biotherapeutics price target raised to $25 from $22 at Oppenheimer
Oppenheimer analyst Mark Breidenbach reiterated an Outperform rating on Iovance Biotherapeutics and raised his price target to $25 from $22 citing recent positive clinical updates for its tumor infiltrating lymphocyte product for melanoma and the outcome of discussions with the FDA regarding the regulatory pathway forward.

TODAY'S FREE FLY STORIES

ZNGA

Zynga

$5.09

-0.01 (-0.20%)

12:20
02/20/19
02/20
12:20
02/20/19
12:20
Options
Defensive option play in Zynga as shares ease off 52-week highs »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

HSY

Hershey

$109.97

0.275 (0.25%)

12:19
02/20/19
02/20
12:19
02/20/19
12:19
Earnings
Hershey issues long-term adjusted EPS growth target of 6%-8% »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

MCS

Marcus

$40.59

1 (2.53%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Marcus raises quarterly dividend 6.7% to 16c per share »

Directors of The Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 02

    Apr

  • 02

    Apr

  • 06

    Jun

HSY

Hershey

$109.95

0.255 (0.23%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Hershey would consider debt to EBITDA ratio over 2.0 times for acquisition »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
02/20/19
02/20
12:17
02/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
02/20/19
02/20
12:16
02/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
02/20/19
02/20
12:15
02/20/19
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

CVS

CVS Health

$64.92

-5 (-7.15%)

, TSLA

Tesla

$302.25

-3.31 (-1.08%)

12:11
02/20/19
02/20
12:11
02/20/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks opened little…

CVS

CVS Health

$64.92

-5 (-7.15%)

TSLA

Tesla

$302.25

-3.31 (-1.08%)

BMY

Bristol-Myers

$51.21

-0.14 (-0.27%)

CELG

Celgene

$91.25

0.54 (0.60%)

KNDI

Kandi Technologies

$8.45

2.52 (42.50%)

GRMN

Garmin

$82.11

11.145 (15.71%)

NVTA

Invitae

$18.55

2.06 (12.49%)

OMI

Owens & Minor

$6.48

-1.46 (-18.39%)

WIX

Wix.com

$110.43

-15.275 (-12.15%)

CXO

Concho Resources

$114.44

-6.51 (-5.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 12

    Mar

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 18

    May

  • 20

    May

  • 22

    May

  • 28

    May

HSY

Hershey

$110.01

0.315 (0.29%)

12:09
02/20/19
02/20
12:09
02/20/19
12:09
Hot Stocks
Hershey reaffirms 2019 guidance at CAGNY Conference »

Hershey said that in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.62

-1.32 (-16.62%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Owens & Minor falls -16.6% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

I

Intelsat

$24.38

2.755 (12.74%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Intelsat rises 12.8% »

Intelsat is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

QUAD

Quad/Graphics

$16.58

2.04 (14.03%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Quad/Graphics rises 14.4% »

Quad/Graphics is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LKSD

LSC Communications

$9.47

1.18 (14.23%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
LSC Communications rises 14.6% »

LSC Communications is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

0.24 (12.06%)

11:58
02/20/19
02/20
11:58
02/20/19
11:58
Hot Stocks
Clean Energy jumps 12% after seeing demand increases for RNG from refuse sector »

Clean Energy Fuels,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 12

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:56
02/20/19
02/20
11:56
02/20/19
11:56
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

DDAIF

Daimler AG

$0.00

(0.00%)

11:48
02/20/19
02/20
11:48
02/20/19
11:48
Periodicals
German prosecutors launch new probe into Daimler, Reuters reports »

Prosecutors in Germany…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

IQ

iQIYI

$22.76

0.43 (1.93%)

11:45
02/20/19
02/20
11:45
02/20/19
11:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 20

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.